Literature DB >> 21834965

Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

Erynn M Boyer1, Martin Turman, Kathleen M O'Neil.   

Abstract

Henoch-Schönlein purpura is one of the most common forms of systemic vasculitis of childhood. We report the response to anakinra, the interleukin-1 receptor antagonist, in a 9 year old girl without prior medical problems who developed life-threatening Henoch-Schönlein vasculitis that produced renal failure, pulmonary hemorrhage and vasculitis of the brain. Her response supports the theory that interleukin-1 may be an important mediator in this disease. Further study of interleukin-1 antagonists in severe Henoch-Schönlein purpura may be warranted.

Entities:  

Year:  2011        PMID: 21834965      PMCID: PMC3169465          DOI: 10.1186/1546-0096-9-21

Source DB:  PubMed          Journal:  Pediatr Rheumatol Online J        ISSN: 1546-0096            Impact factor:   3.054


  43 in total

Review 1.  Current state of biologicals in the management of systemic vasculitis.

Authors:  Peter Lamprecht; Andreas Till; Jörg Steinmann; Peer M Aries; Wolfgang L Gross
Journal:  Ann N Y Acad Sci       Date:  2007-09       Impact factor: 5.691

Review 2.  Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature.

Authors:  F T Saulsbury
Journal:  Medicine (Baltimore)       Date:  1999-11       Impact factor: 1.889

3.  Clinical outcome in children with Henoch-Schönlein nephritis.

Authors:  Sevgi Mir; Onder Yavascan; Fatma Mutlubas; Betul Yeniay; Ferah Sonmez
Journal:  Pediatr Nephrol       Date:  2006-09-21       Impact factor: 3.714

4.  Henoch-Schönlein purpura in a child with hyperimmunoglobulinemia D and periodic fever syndrome.

Authors:  Jonathan E Wickiser; Frank T Saulsbury
Journal:  Pediatr Dermatol       Date:  2005 Mar-Apr       Impact factor: 1.588

5.  Febrile myalgia syndrome in familial Mediterranean fever.

Authors:  Alper Soylu; Belde Kasap; Mehmet Türkmen; Gül Sağn Saylam; Salih Kavukçu
Journal:  J Clin Rheumatol       Date:  2006-04       Impact factor: 3.517

6.  Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide.

Authors:  Penina Tarshish; Jay Bernstein; Chester M Edelmann
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

7.  Variable expression of vasculitis in siblings with familial Mediterranean fever.

Authors:  Bärbel Lange-Sperandio; Klaus Möhring; Frank Gutzler; Otto Mehls
Journal:  Pediatr Nephrol       Date:  2004-03-11       Impact factor: 3.714

8.  Henoch-Schönlein nephritis: a nationwide study.

Authors:  O Soylemezoglu; O Ozkaya; S Ozen; A Bakkaloglu; R Dusunsel; H Peru; A Cetinyurek; N Yildiz; O Donmez; N Buyan; S Mir; N Arisoy; A Gur-Guven; H Alpay; M Ekim; N Aksu; A Soylu; F Gok; H Poyrazoglu; F Sonmez
Journal:  Nephron Clin Pract       Date:  2009-05-13

9.  Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression.

Authors:  Mohan Shenoy; Mark G Bradbury; Malcolm A Lewis; Nicholas J A Webb
Journal:  Pediatr Nephrol       Date:  2007-07-24       Impact factor: 3.714

10.  Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schönlein purpura.

Authors:  Ruth Gershoni-Baruch; Yiftah Broza; Riva Brik
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

View more
  9 in total

Review 1.  An expanding role for interleukin-1 blockade from gout to cancer.

Authors:  Charles Anthony Dinarello
Journal:  Mol Med       Date:  2014-12-16       Impact factor: 6.354

2.  Biologics for immunoglobulin A vasculitis: targeting vasculitis or comorbid disease?

Authors:  Bayram Farisogullari; Muserref Kasap Cuceoglu; Hakan Oral; Gozde Kubra Yardimci; Yelda Bilginer; Seza Ozen; Omer Karadag
Journal:  Intern Emerg Med       Date:  2022-03-26       Impact factor: 5.472

Review 3.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

Review 4.  Of Inflammasomes and Alarmins: IL-1β and IL-1α in Kidney Disease.

Authors:  Hans-Joachim Anders
Journal:  J Am Soc Nephrol       Date:  2016-08-11       Impact factor: 10.121

Review 5.  The Future of IL-1 Targeting in Kidney Disease.

Authors:  Baris Afsar; Adrian Covic; Alberto Ortiz; Rengin Elsurer Afsar; Mehmet Kanbay
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 6.  Treating inflammation by blocking interleukin-1 in humans.

Authors:  Charles A Dinarello; Jos W M van der Meer
Journal:  Semin Immunol       Date:  2013-11-23       Impact factor: 11.130

Review 7.  Kawasaki disease: pathophysiology and insights from mouse models.

Authors:  Magali Noval Rivas; Moshe Arditi
Journal:  Nat Rev Rheumatol       Date:  2020-05-26       Impact factor: 20.543

Review 8.  Henoch-Schönlein Purpura in children: not only kidney but also lung.

Authors:  Giada Maria Di Pietro; Massimo Luca Castellazzi; Antonio Mastrangelo; Giovanni Montini; Paola Marchisio; Claudia Tagliabue
Journal:  Pediatr Rheumatol Online J       Date:  2019-11-21       Impact factor: 3.054

Review 9.  Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.